Editor's Choice
The performance of the Elecsys® anti-Müllerian hormone assay in predicting extremes of ovarian response to corifollitropin alfa
What is the performance of anti-Müllerian hormone (AMH) as measured by the Elecsys® AMH assay in predicting ovarian response in women treated with 150 µg corifollitropin alfa (CFA)?Ovarian tissue cryopreservation in female-to-male transgender people: insights into ovarian histology and physiology after prolonged androgen treatment
Female-to-male transgender people (trans men), are faced with the risk of losing their reproductive potential owing to gender affirming hormone treatment and genital reconstructive surgery. Transgender people also tend to start sex reassignment treatment at a young age, when reproductive wishes are not yet clearly defined nor fulfilled (De Sutter, 2001). About one-half of trans men, however, express the desire to have children (Wierckx et al., 2012). It is, therefore, recommended by the most recent Standards of Care of the World Professional Association for Transgender Health to clearly discuss fertility and fertility preservation before any treatment (Coleman et al., 2012).Anti-Müllerian hormone kinetics in pregnancy and post-partum: a systematic review
The aim of this systematic review is to critically appraise the available evidence regarding the kinetics of anti-Müllerian hormone (AMH) during pregnancy and post-partum. A systematic literature search was conducted in MEDLINE, Embase, CENTRAL, Scopus and Web of Science on 14 December 2015, aiming to identify studies providing data on the serum concentration of AMH in women at various stages of gestation and post-partum. There was a total of 1719 participants across eight studies. Seven out of the eight studies reported a decline in serum AMH concentration with advancing gestational age.
